{"id":"NCT04209634","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)","officialTitle":"An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-01-27","primaryCompletion":"2021-11-09","completion":"2024-05-02","firstPosted":"2019-12-24","resultsPosted":"2023-10-30","lastUpdate":"2025-08-29"},"enrollment":10,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["CD55-deficient Protein-losing Enteropathy","CHAPLE"],"interventions":[{"type":"DRUG","name":"Pozelimab","otherNames":["REGN3918"]}],"arms":[{"label":"Active PLE","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to determine the effect of pozelimab on active CD55-deficient protein-losing enteropathy (PLE; CHAPLE).\n\nThe secondary objectives of the study are:\n\n* To evaluate the safety and tolerability of pozelimab in patients with CD55-deficient PLE disease\n* To evaluate the effect of pozelimab on CD55-deficient PLE (both patients with active disease at baseline and those with inactive disease on eculizumab, switching to pozelimab)\n* To determine the effects of pozelimab on albumin and other serum proteins (total protein, immunoglobulins)\n* To determine the effects of pozelimab on ascites\n* To determine the effects of pozelimab on stool consistency\n* To determine the effect of pozelimab on health-related quality of life\n* To determine the effect of pozelimab on lab abnormalities observed in CD55-deficient PLE such as hypertriglyceridemia, thrombocytosis, and hypovitaminosis B12\n* To describe the effects of pozelimab on the sparing of concomitant medications and reduction in hospitalization days\n* To determine the effects of pozelimab on growth\n* To characterize the concentration of pozelimab in patients with CD55-deficient PLE\n* To assess the incidence of treatment-emergent ADA for pozelimab in patients with CD55-deficient PLE disease","primaryOutcome":{"measure":"Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24","timeFrame":"At Week 24","effectByArm":[{"arm":"Pozelimab Injection","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":3,"countries":["United States","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["39934837","39118150","38278170"],"seeAlso":["https://www.trialsummaries.com/"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":10},"commonTop":["Abdominal pain","Vomiting","Nasopharyngitis","Upper respiratory tract infection","Rhinitis"]}}